Liver Cancer (Hepatocellular Carcinoma) clinical trials in Pennsylvania
35 active Liver Cancer (Hepatocellular Carcinoma) trials with a site in Pennsylvania. Describe your situation to see which ones look like a fit.
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- SBRT With Atezo/Bev for HCC
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Y-90 Treatment Response Using Transarterial Radioembolization
- National Liver Cancer Screening Trial
- Observational Study Protocol: LIVER-R
- Molecular Basis of Pediatric Liver Cancer
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
- LTFU for All Cell and Gene Therapy Studies
- Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Getting To Implementation: Improving Cancer Screening for Veterans
- A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.